Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials

PURPOSE: Measures of response that are clinically meaningful and occur early are an unmet need in metastatic castration-resistant prostate cancer clinical research and practice. We explored, using individual patient data, week 13 circulating tumor cell (CTC) and prostate-specific antigen (PSA) respo...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Heller, Glenn, McCormack, Robert, Kheoh, Thian, Molina, Arturo, Smith, Matthew R., Dreicer, Robert, Saad, Fred, de Wit, Ronald, Aftab, Dana T., Hirmand, Mohammad, Limon, Ana, Fizazi, Karim, Fleisher, Martin, de Bono, Johann S., Scher, Howard I.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2018
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5815402/
https://ncbi.nlm.nih.gov/pubmed/29272162
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.75.2998
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi